422 Rehab Centers in
Barbital
Inpatient and Outpatient Barbital Addiction Treatment in Tennessee
Barbital dependency often requires medically supervised detox and structured recovery support due to serious withdrawal risks. Browse our Tennessee directory below to explore inpatient rehab, outpatient programs, sedative-hypnotic detox centers, and licensed counselors specializing in barbiturate abuse and substance use disorder recovery.
Whether you need residential care, intensive outpatient treatment, or ongoing therapy for barbital addiction, our listings make comparing local providers easy. Every facility and clinician featured here is human-vetted by our quality raters for credentials, authenticity, and service before appearing in our directory.
Why Trust Treatmenttennessee
Evidence and ethics matter to us. Since 2025, our expert team has built comprehensive resources you can trust to find the right treatment for you.
Unbiased and independent resource
100% editorially independent with no provider affiliations.
Accurate & comprehensive information
Comprehensive provider profiles backed by 1+ years of research.
We are trusted by millions
Helped more than 100+ families with recovery.
We adhere to ethical standards
Direct provider connections; we don’t profit from referrals.
Explore Popular Rehab Centers
Virtual Outpatient (Telehealth)
Cedar Recovery Shelbyville
Shelbyville, TN 37160
Accepts Insurance
Cedar Recovery is a well-established facility dedicated to supporting individuals on their journey to recovery. The center provides a structured, compassionate environment that prioritizes personalized….
Best Addiction & Mental Health Treatment Rehab Facilities by Barbital
Why Trust TreatmentTennessee
Evidence and ethics matter to us. Since 2025, our expert team has built comprehensive resources you can trust to find the right treatment for you.
Unbiased and independent resource
100% editorially independent with no provider affiliations.
Accurate & comprehensive information
Comprehensive provider profiles backed by 1+ years of research.
We are trusted by millions
Helped more than 100+ families with recovery.
We adhere to ethical standards
Direct provider connections; we don’t profit from referrals.
Barbital Addiction: Understanding Risks, Withdrawal, and Treatment in Tennessee
Educational resource from TreatmentTennessee.com — reviewed for accuracy and aligned with current public health terminology.
Barbital, sold historically under the brand name Veronal, was the first barbiturate ever introduced into clinical medicine, dating back to 1903. While it has been almost entirely phased out of modern American pharmacies, barbital and chemically related long-acting barbiturates still surface in cases of substance misuse, particularly among individuals using older medication stock, compounded prescriptions, or research-grade sedatives obtained outside regulated channels. This page explains what barbital is, why it carries serious risk, and where Tennessee residents can find evidence-based help.
What Is Barbital?
Barbital (diethylbarbituric acid) is a long-acting barbiturate, a class of central nervous system depressant that works by enhancing the activity of gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. Barbital was synthesized in the late 1800s and became the first barbiturate marketed for medical use, prescribed primarily as a sedative-hypnotic for insomnia and anxiety in the early 20th century. Because of its long duration of action — often 10 to 12 hours or longer — barbital tended to accumulate in the body with repeated dosing, increasing the likelihood of unintentional overdose even when used as directed by physicians of that era.
By the mid-20th century, barbital and similar barbiturates were gradually replaced in mainstream medicine by benzodiazepines, which carry a wider margin of safety between an effective dose and a fatal dose. Today, barbital has no approved medical indication in the United States and is rarely encountered in contemporary clinical settings. According to the U.S. Drug Enforcement Administration, barbiturates as a drug class remain controlled substances due to their potential for misuse and dependence, even though prescribing of older compounds like barbital has been discontinued in routine practice.[1]
Drug Class
Long-acting barbiturate, central nervous system depressant, Schedule III/IV controlled substance category depending on formulation.
Historical Use
Introduced in 1903 as a sedative-hypnotic; largely discontinued in U.S. clinical practice by the 1970s and 1980s.
Primary Risk
Narrow therapeutic index — the gap between a typical dose and a fatal dose is small, raising overdose risk with repeated use.
Why Barbital Still Matters Today
Although barbital itself is uncommon in current prescribing, understanding it remains relevant for several reasons. Some older adults may still have legacy prescriptions or family medicine cabinets containing decades-old barbiturate compounds. Barbital and closely related long-acting barbiturates also appear occasionally in forensic toxicology, veterinary settings, and research or industrial chemical contexts, creating limited but real pathways to non-medical use. In addition, individuals with a history of sedative-hypnotic use disorder involving phenobarbital, butalbital, or other barbiturates may have prior exposure to barbital-class compounds, and treatment professionals in Tennessee need to recognize the shared withdrawal and overdose risks across this drug family.
The Centers for Disease Control and Prevention tracks overdose deaths involving sedative-hypnotic drugs as part of its broader surveillance of substance-involved mortality, and while barbiturate-specific deaths are now a small fraction of overall drug deaths compared to opioids, they still carry some of the highest case-fatality rates of any depressant class because of how easily a sedating dose can become a respiratory-suppressing one.
How Barbital Affects the Brain and Body
Barbital depresses activity throughout the central nervous system by binding to GABA-A receptors and prolonging the opening of chloride channels in neurons. This produces sedation, muscle relaxation, and reduced anxiety at lower doses, but at higher doses it suppresses the brain’s respiratory drive. Tolerance to the sedative effects of barbital develops relatively quickly with repeated use, while tolerance to its respiratory-depressant effects develops more slowly — a mismatch that explains why people who increase their dose to chase the original calming effect can unintentionally reach a dose that stops breathing altogether.
Combining barbital with alcohol, opioids, or benzodiazepines compounds this danger substantially, since all of these substances depress respiration through overlapping pathways. The National Institute on Drug Abuse notes that polysubstance use involving multiple central nervous system depressants is a leading contributor to fatal overdose, underscoring why any sedative-hypnotic use, including legacy barbiturates like barbital, should be addressed by a qualified treatment provider rather than self-managed.
Signs of Barbital Misuse
Slurred speech, poor coordination, drowsiness disproportionate to dose, confusion, slowed breathing, irritability between doses, difficulty stopping use despite a desire to quit, and continued use even after experiencing withdrawal symptoms when a dose is missed. Family members may also notice doctor-shopping behavior or unexplained shortages of medication.
Barbital Withdrawal: A Medical Emergency
Withdrawal from long-acting barbiturates such as barbital is considered one of the more medically dangerous withdrawal syndromes among all substances, comparable in severity to alcohol and benzodiazepine withdrawal. Because barbital has a long half-life, withdrawal symptoms can be delayed by several days after the last dose, which sometimes leads people to mistakenly believe they have safely stopped using the substance before symptoms actually begin.
Unsupervised barbiturate withdrawal can produce seizures, severe agitation, hallucinations, dangerously elevated body temperature, and cardiovascular instability. For this reason, the Substance Abuse and Mental Health Services Administration recommends that anyone discontinuing long-term barbiturate use do so under medical supervision, typically through a gradual, monitored tapering schedule rather than abrupt cessation. Tennessee residents considering stopping barbiturate use should contact a licensed detoxification provider before reducing or discontinuing their dose on their own.
Important: Never stop barbiturate use abruptly without medical guidance. Sudden discontinuation after regular, prolonged use can trigger life-threatening seizures. A medically supervised taper, often delivered through an inpatient or licensed outpatient detox program, is the recommended approach.
Treatment Approaches for Barbiturate Use Disorder
Because barbital and related barbiturates are no longer commonly prescribed, treatment for a sedative-hypnotic use disorder involving this drug class typically follows the broader clinical pathway used for any barbiturate or depressant-related substance use disorder. Effective treatment usually involves several stages.
Medical Detoxification
A supervised taper reduces the barbital dose gradually, often substituting a longer-acting agent to stabilize blood levels while symptoms are monitored around the clock. This phase is typically completed in an inpatient or residential detox setting given the seizure risk involved.
Inpatient or Residential Rehabilitation
Following detox, many individuals benefit from a structured residential program that addresses the behavioral and psychological patterns connected to sedative use, including any co-occurring anxiety or sleep disorders that may have originally prompted barbiturate use.
Outpatient Counseling and Therapy
Cognitive behavioral therapy and motivational interviewing are commonly used to help individuals identify triggers, build coping skills, and address the anxiety or insomnia that often underlies long-term sedative use.
Co-Occurring Disorder Care
Many people who develop a sedative-hypnotic use disorder also experience generalized anxiety, panic disorder, or insomnia. Integrated treatment that addresses both conditions at once tends to produce more durable outcomes than treating either issue in isolation.
Peer Support and Aftercare
Ongoing peer support, whether through twelve-step models or secular alternatives, helps sustain recovery after formal treatment ends. Many people find that combining professional aftercare with a community support group improves long-term stability.
Support Groups and Nonprofit Resources
Several organizations offer no-cost peer support relevant to people recovering from sedative or depressant-related substance use disorders, including barbiturate misuse:
- SMART Recovery — a free, secular, self-empowerment-based mutual support program with meetings across Tennessee and online.
- Narcotics Anonymous — a twelve-step fellowship open to anyone working to recover from any substance use disorder, including sedative-hypnotic dependence.
- SAMHSA National Helpline — a free, confidential, 24/7 treatment referral and information service in English and Spanish.
- National Alliance on Mental Illness (NAMI) Tennessee — support for individuals managing co-occurring anxiety, insomnia, or other mental health conditions alongside substance use.
Finding Barbiturate Use Disorder Treatment in Tennessee
TreatmentTennessee.com maintains a directory of vetted behavioral health and addiction treatment providers across the state. Detoxification from long-acting barbiturates requires medical supervision, so we encourage anyone seeking help to look for facilities offering licensed, medically managed withdrawal services before pursuing residential or outpatient rehabilitation. Explore providers by region below:
Related Topics
For information on related sedative-hypnotic substances and co-occurring conditions, see our pages on:
Frequently Asked Questions
Is barbital still prescribed in the United States?
No. Barbital has been essentially discontinued from American clinical practice for decades, replaced by safer sedative-hypnotic medications. It may still appear in older medicine supplies, research settings, or imported products.
Can barbital withdrawal be fatal?
Yes. Abrupt withdrawal from long-acting barbiturates can cause seizures and other life-threatening complications, which is why medical supervision during tapering is strongly recommended.
How is barbiturate use disorder treated differently from opioid use disorder?
Unlike opioid use disorder, there is no FDA-approved medication-assisted maintenance treatment for barbiturate dependence. Treatment instead centers on a gradual, medically managed taper followed by behavioral therapy and relapse-prevention support.
What should I do if I find old barbiturate medication at home?
Do not use it. Dispose of unused or expired barbiturate medication through a DEA-authorized drug take-back location or program rather than keeping it in the home.
Looking for Treatment Support in Tennessee?
Browse our directory of verified behavioral health and addiction treatment providers across the state.
References and Citations
- U.S. Drug Enforcement Administration, Diversion Control Division — Barbiturates Drug Fact Sheet
- Centers for Disease Control and Prevention — Drug Overdose Surveillance and Data
- National Institute on Drug Abuse — Polysubstance Use Facts
- Substance Abuse and Mental Health Services Administration — Medications for Substance Use Disorders and Withdrawal Management
- National Institute on Drug Abuse — Words Matter: Terms to Use and Avoid When Talking About Addiction
This article is for educational purposes only and does not constitute medical advice. Please consult a licensed healthcare provider before making decisions about discontinuing any medication.
